Release Date: 2024-02-12

Gene Therapy in Neurological Diseases

Mehmet Ufuk Aluclu (Author)

Release Date: 2024-02-12

Gene therapy methods have gained importance in the fi eld of neurology in recent years and have begun to be used especially in the treatment of neurological disorders of genetic origin. Gene therapy aims to correct pathologies, neuroprotection, neurorestoration and correct clinical fi ndings in neurological diseases. Gene transfer treatments, in which artifi cial transgenes [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inGene Therapy
    First Page93
    Last Page105
    DOIhttps://doi.org/10.69860/nobel.9786053358824.6
    Page Count13
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Gene therapy methods have gained importance in the fi eld of neurology in recent years and have begun to be used especially in the treatment of neurological disorders of genetic origin. Gene therapy aims to correct pathologies, neuroprotection, neurorestoration and correct
    clinical fi ndings in neurological diseases. Gene transfer treatments, in which artifi cial transgenes are inserted into cells to correct the lack of expression of a damaged gene, are being tried to be provided through experimental studies for many neurological diseases.

    Mehmet Ufuk Aluclu (Author)
    Professor, Dicle University
    https://orcid.org/0000-0001-5876-8643
    3Professor Mehmet Ufuk ALUÇLU, after completing his medical education (1984-1990) and neurology education (1993-1997) at Dicle University Faculty of Medicine, was appointed Assistant Professor in 1998, Associate Professor in 2007, and Professor in 2013 at Dicle University Faculty of Medicine, Department of Neurology. happened. I have been working as a Professor and Head of the Department of Neurology at Dicle University Faculty of Medicine, Department of Neurology since 2013. I am a member of the Turkish Neurology Association and the Turkish Epilepsy Combat Association, and I participate in the activities of the Turkish Neurology Association-Multiple Sclerosis and the Turkish Neurology Association-Neurorehabilitation Working Group.

    • Simonato M, Bennett J, Boulis NM, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2020;16(2):77-92.

    • Coorey BA, Gold WA. Breaking Boundaries in the Brain-Advances in Editing Tools for Neurogenetic Disorders. Front Genome Ed. 2021;1;3:623519.

    • Trapani I, Auricchio A. Seeing the Light after 25 Years of Retinal Gene Therapy. Trends Mol Med. 2018;24(9):669-681.

    • Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN. et.al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021;3;29(2):464-488.

    • Kariyawasam D, Alexander IE, Kurian M, Farrar MA Great expectations: virus- mediated gene therapy in neurological disorders. J Neurol Neurosurg Psychiatry. 2020;91(8):849-860.

    • Morris G, Schorge S. Gene Therapy for Neurological Disease: State of the Art and Opportunities for Next-generation Approaches. Neuroscience. 2022;10;490:309-314.

    • Snyder EY, Fisher LJ. Gene therapy in neurology. Curr Opin Pediatr. 1996;8(6):558- 68.

    • Ingusci S, Verlengia G, Soukupova M, Zucchini S, Simonato M. Gene Therapy Tools for Brain Diseases. Front Pharmacol. 2019;1;10:724.

    • Choong CJ, Baba K, Mochizuki H. Gene therapy for neurological disorders. Expert Opin Biol Ther. 2016;16(2):143-59.

    • Holm A, Hansen SN, Klitgaard H, Kauppinen S.Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. RNA Biol. 2022;19(1):594-608.

    • Chen W, Hu Y, Ju D. Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B. 2020;10(8):1347-1359.

    • Anthony K. RNA-based therapeutics for neurological diseases. RNA Biol. 2022;19(1):176-190.

    • Sudhakar V, Richardson RM. Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics. 2019;16(1):166-175.

    • Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.N Engl J Med. 2017;2;377(18): 1713-1722.

    • Millington-Ward S, Chadderton N, O’Reilly M, Palfi A, Goldmann T, Kilty C, et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther. 2011;19(4):642-9.

    • Suzuki M, Kasai K, Saeki Y. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol. 2006;80(7):3293-300.

    • Shahryari A, Saghaeian Jazi M, Mohammadi S, Razavi Nikoo H, Nazari Z, Hosseini ES, et al. Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Front Genet. 2019;25;10:868.

    • Glorioso JC, Cohen JB, Carlisle DL, Munoz-Sanjuan I, Friedlander RM. Moving toward a gene therapy for Huntington’s disease. Gene Ther. 2015;22(12):931-3.

    • Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting Huntingtin Expression in Patients with Huntington’s Disease. N Engl J Med. 2019 Jun 13;380(24):2307-2316.

    • Axelsen TM, Woldbye DPD Gene Therapy for Parkinson’s Disease, An Update. J Parkinsons Dis. 2018;8(2):195-215.

    • Elsworth JD. Parkinson’s disease treatment: past, present, and future.. J Neural Transm (Vienna). 2020;127(5):785-791.

    • Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021;3;29(2):464-488.

    • Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284-293.

    • Zakharova M.Modern approaches in gene therapy of motor neuron diseases. Med Res Rev. 2021;41(5):2634-2655.

    • Honig LS. Gene Therapy in Alzheimer Disease-It May Be Feasible, but Will It Be Beneficial? JAMA Neurol. 2018;1;75(7):791-793.

    • Gupta AO, Raymond G, Pierpont EI, Kemp S, McIvor RS, Rayannavar A, et al. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy. Expert Opin Biol Ther. 2022;22(9):1151-1162.

    • Lauer A, Speroni SL, Choi M, Da X, Duncan C, McCarthy S, et al. Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy. Nat Commun. 2023; 5;14(1):1900.

    • Mallack EJ, Turk B, Yan H, Eichler FS. The Landscape of Hematopoietic Stem Cell Transplant and Gene Therapy for X-Linked Adrenoleukodystrophy. Curr Treat Options Neurol. 2019; 25;21(12):61.

    • Pisciotta C, Pareyson D. Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease. Neuromuscul Disord. 2023;33(8):627-635.

    • Sargiannidou I, Kagiava A, Kleopa KA. Gene therapy approaches targeting Schwann cells for demyelinating neuropathies. Brain Res. 2020;1;1728:146572.

    • Mendonça RH, Zanoteli E. Gene therapy in neuromuscular disorders. Arq Neuropsiquiatr. 2022;80(5):249-256.

    • Elangkovan N, Dickson G.Gene Therapy for Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021;8(s2):S303-S316.

    • Keeler GD, Kumar S, Palaschak B, Silverberg EL, Markusic DM, Jones NT, et al. Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis. Mol Ther. 2018 Jan 3;26(1):173-183.

    • Turner TJ, Zourray C, Schorge S, Lignani G.Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. J Neurochem. 2021;157(2):229-262.

    • Boileau C, Deforges S, Peret A, Scavarda D, Bartolomei F, Giles A, et al. GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy. Ann Neurol. 2023;94(4):745-761.

    • Zhang L, Wang Y. Gene therapy in epilepsy. Biomed Pharmacother. 2021;143:112075.

    • Chilcott E, Díaz JA, Bertram C, Berti M, Karda R.Genetic therapeutic advancements for Dravet Syndrome. Epilepsy Behav. 2022;132:108741.

    • Walker MC, Schorge S, Kullmann DM, Wykes RC, Heeroma JH, Mantoan L. Gene therapy in status epilepticus.Epilepsia. 2013;54:43-5.

    • Lejman J, Panuciak K, Nowicka E, Mastalerczyk A, Wojciechowska K, Lejman M. Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. Int J Mol Sci. 2023 ;6 ;24(2): 1130.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!